The identification of genes inducing resistance t o anticancer chemotherapeutic agents and their introduction into hematopoietic cells represents a promising approach t o overcome bone marrow toxicity, the limiting factor for most high-dose chemotherapy regimens. Because resistance t o cyclophosphamide has been correlated with increased levels of expression of the aldehyde-dehydrogenase (ALDH1) gene in tumor cell lines in vitro, we tested whether ALDHl overexpression could directly induce cyclophosphamide resistance. We have cloned a full-length human ALDHl cDNA and used retroviral vectors t o transduce it into human (U9371 and murine (L1210) hematopoietic cell lines that were then tested for resistance t o maphosphamide, an active analogue of cyclophosphamide. Overexpression of the ALDHl gene resulted IGH-DOSE CHEMOTHERAPY, including high-dose and high-dose-intensive regimens, represents a promising approach to improve therapeutic results in a variety of human tumors.' The limiting factor in most high-dose protocols is myelotoxicity, a problem that has only partially been solved by the use of hematopoietic growth factors.' In fact, presently available growth factors alleviate, but do not prevent, drug-induced myelotoxicity, particularly in those situations in which the bone marrow reserve is inadequate because of previous treatment with myelotoxic agent^.^ To resolve this problem, gene transfer strategies aimed at conferring drug resistance to hematopoietic cells are being developed." Towards this end, two genes have been identified for their activity in conferring resistance to therapeutic drugs, a mutant dihydrofolate reductase gene (DHF'Rr) coding for an enzyme with reduced affinity to methotrexate5 and the human multidrug-resistance gene 1 (MDR1).6 However, the application of these drug-resistance strategies is limited to a subset of chemotherapeutic drugs, methotrexate in the case of DHFRr and xenobiotics (mainly taxanes) in the case of MDRl Cyclophosphamide is one of the most commonly used alkylating agents in chemotherapeutic regimens because it has a broad antitumor spectrum, a low risk of inducing chemoresistance, and a limited hematopoietic toxicity.' Its use in high-dose regimens, in association with hematopoietic growth factors, has led to improved therapeutic These results have provided strong support for the notion that further increases in drug dose or intensity may lead to further therapeutic improvements.
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Increasing evidence suggests that the cytosolic enzyme aldehyde-dehydrogenase (ALDHl) may be involved in the mechanisms of cellular resistance to cyclophosphamide."." In murine pluripotent hematopoietic' stem cells (spleen colony-forming units) and myeloid progenitor cells (granulocyte-macrophage colony-forming units) inhibition of ALDHl activity correlates with increased in vitro sensitivity to 4-hydro~ycyclophosphamide,'~ ie, the active metabolite of cyclophosphamide. In human hematopoietic progenitor cells (HPCs), a correlation has been made between cyclophosphamide resistance and ALDHl levels during hemato- in a significant increases in cyclophosphamide resistance in transduced L1210 and U937 cells (50% inhibition concentration [IC,], =13pmol/L). The resistant phenotype was specifically caused by ALDHl overexpression as shown by its reversion by disulfiram, a specific ALDHl inhibitor. ALDHl transduction into peripheral blood human hematopoietic progenitor cells also led t o significant increases (4-t o 10-fold; IC5,,, -3 t o 4 pmol/L) in cyclophosphamide resistance in an in vitro colony-forming assay. These findings indicate that ALDHl overexpression is sufficient t o induce cyclophosphamide resistance in vitro and provide a basis for testing the efficacy of ALDHl gene transduction t o protect bone marrow cells from high-dose cyclophosphamide in vivo. 0 1996 b y The American Society of Hematology.
poietic differentiation." However, a direct role of the enzyme in inducing cyclophosphamide resistance has not been formally shown.
This study was aimed at directly testing whether the overexpression of the ALDHl gene could induce cyclophosphamide resistance as a basis for the eventual use of ALDHl in gene therapy strategies in vivo. We have cloned a fulllength ALDHl cDNA and used retroviral vectors to transduce it into hematopoietic cell lines and into human HPCs that were then tested for resistance to maphosphamide, an active analogue of cyclophosphamide. The results indicate that ALDHl is sufficient to induce cyclophosphamide resistance and suggest that the ALDHl gene may be useful in generating hematopoietic cells resistant to cyclophosphamide in vivo.
MATERIALS AND METHODS

Cloning of a full-length human A D H l cDNA.
A human liver cDNA library (HLI 115A; Clontech, Palo Alto, CA) was screened with a partial ALDHl probe corresponding to 1560 bp of ALDHl cDNA sequences, lacking 5' coding sequence^'^ (a gift from Dr. L.C. Hsu). A partial cDNA clone, pGALDHI-A, was isolated containing 1471-bp coding sequences and 272-bp 3' untranslated sequences, but still lacking 46 bp of 5' coding sequences including the translation initiation codon. To obtain the remaining 5' coding sequences, human genomic DNA was amplified by polymerase chain reaction (PCR) using a S'-end primer spanning S' flanking sequencesIs and a 3'-end primer internal to the coding sequences in the cDNA. For subcloning purposes, the primers contained a 5' artificial Xba I site and a 3' Bgl I1 site present in the cDNA. After Xba I and Bgl I1 digestion, the PCR product was subcloned into pGALDH1-A leading to the 1506-bp full-length ALDHl cDNA, pGAldo. The PCR-generated Xba I-Bgl I1 fragment of pGAldo was verified by nucleotide sequencing.
Construction To generate amphotropic packaging cell lines, the pAldoX and pN2a-Aldo plasmids were transfected into PA317 cells (CRL 9078; American Type Culture Collection, Rockville, MD) by the CaPO, precipitation method." pSV2ne0, which carries a neomycin-resistance gene (Clontech), was cotransfected in each case to provide a marker for the selection of the transfected cells. After cotransfection, the cells were selected in Iscove's modified Dulbecco's medium (IMDM) containing G418 (active dose, 0.5 mg/mL), 10% calf serum, and 1 % penicillin-streptomycin (GIBCO-BRL, Gaithersburg, MD). High-titer-producing clones were identified by testing the supernatant of multiple neo-resistant clones on NIH3T3 cells and determining the relative number of infected cells by Southern blot analysis using probes specific for the transduced ALDHl sequences.'" Infection of hematopoietic cell lines and ident$cation of ALDHItransduced clones. L1210 and U937 (American Type Culture Collection) cell lines were transduced by incubation of 10' cells with I mL of filtered viral supernatant, in the presence of protamine sulfate (S pg/mL; Sigma, St Louis, MO), for 24 hours; the incubation was repeated for 3 consecutive days, with replacement of the viral supernatant every 24 hours. Cells were then washed twice with phosphatebuffered saline (PBS) and plated in RPM1 1640 (L1210) or IMDM (U937) medium containing 20% fetal bovine serum, I% penicillinstreptomycin, and 10 pmol/L P-mercaptoethanol (Sigma) by a modification of the limiting dilution liquid colture assay described by Ventura et al."' DNA was isolated from colonies grown in single wells" and was subjected to 30 cycles of PCR amplification with primers specific for ALDHl cDNA. Amplification of ALDH I cDNA by these primers resulted in an amplified fragment of 431 bp, detected by l S% agarose gel electrophoresis and staining with ethidium-bromide.
Maphosphamide cytotoxicity assay in transduced cell lines. Maphosphamide (ASTA Z 7557; a gift of Dr Pohl, Asta Werke, Bielefeld, Germany) was obtained as a pure white powder and kept at -20°C. A I-mmol/L solution was prepared with PBS and sterilized by filtration (0.25 pm) immediately before use. Maphosphamide resistance was assayed by a modification of the protocol described by Kaizer et al.?' Briefly, cells transduced with the different vectors were resuspended at 10'' cells/mL in regular medium and were incubated with increasing doses of maphosphamide for 30 minutes at 37°C in a water bath with frequent agitation. After this period, cells were cooled on ice, washed twice with cold Hanks' balanced salt solution, and plated in quadruplicate at 5 X 10' (L1210) or IO4 (U937) cells/well in a 96-well microtiter plate.
After 3 days of culture, a period during which the growth curve of unselected cells was shown to remain linear (not shown), cell viability was assessed by the tetrazolium salt (MTT; [Sigma] colorimetric assay." A total of 20 pL of a 6.5-mg/mL solution of MTT in PBS was added to each well of the 96-well microtiter plate and incubated for 2 hours at 37°C. After this incubation period, 100 pL of solubilization buffer (sodium dodecyl sulfate 20% in SO% N,Ndimethylformamide, pH 4.7) were added, and the incubation continued overnight. The optical densities at 570 nm were then measured using 20 pL of MTT and 100 pL of extraction buffer in complete medium as a blank control.
The calculation of the 50% inhibition concentration (IC5") for each clone was performed using the Probit analysis method.z4
RNA analysis. RNA obtained by the Trizol reagent purification procedure (GIBCO-BRL) was resuspended in diethylpyrocarbonate (Sigma)-treated water and was analyzed by 0.9% agarose, 6% formaldehyde, 1 X 3-(N-morpholino) propanesulfonic acid (MOPS), gel electrophoresis. Each lane was loaded with 20 pg of total RNA in S% formaldehyde and 45% formamide in a 40-pL total volume containing 4 pL of IOX running dye. Gels were run at a constant voltage of 2 V/cm overnight in 1 X MOPS running buffer. Overnight transfer to nitrocellulose and subsequent procedures were performed as described." Ethidium-bromide staining was used to determine the integrity of the RNA by inspection of the gels. Filters were hybridized to the ALDHl cDNA probe as described above. Normalization of the quantity of RNA transferred to the filters was obtained after stripping the filters, as suggested by the manufacturer, and hybridization with a 1.4-kb GAPDH probe as described above.
Disulfiram inhibition assay. Disulfiram (Sigma), a specific inhibitor of aldehyde-dehydrogenase activity," was dissolved in 95% ethanol, used within 1 hour of preparation, and kept at +4"C prior to its use. At the concentrations used, ethanol was not cytotoxic to the cells (not shown). Cells were incubated with disulfiram for 30 minutes at 37°C. Maphosphamide was then added and the incubation was continued for an additional 30 minutes at 37°C.
Assuy ojALDHI uctivity. Briefly, as previously described,'" protein lysates from infected clones were incubated in a reaction mixture containing 32 mmoVL sodium pyrophosphate buffer [pH 8.21, S mmol/L N-acetyl-l-cysteine (Sigma), 0. I mmoliL 4-methylpyrazole, 4 mmol/L NAD', 1 mmoln disodium salt EDTA, and 4 mmoL/L acetaldehyde. A blank reaction, identical to the above but without acetaldehyde, was run for each sample. The reaction was run at 37°C monitoring the change of optical density at a wavelength of 340 nm. A standard curve was calculated with different amounts of yeastpurified ALDH enzyme (Sigma).
Western blotting. Cell extracts from L1210 (IO7) or U937 (2.6 X IO7) cells were analyzed by Western immunoblotting as previously described".'* with a polyclonal antihuman ALDHl rabbit antiserum" (a kind gift of Dr A. Yoshida, Beckman Research Institute of the City of Hope, Duarte, CA) followed by incubation with horseradish peroxidase-conjugated Protein-A (Boehringer Mannheim, Indianapolis, IN) for 60 minutes. Bands were visualized by enhanced chemiluminescence (ECL; Amersham, Arlington Heights, IL). Probing with anti-&actin monoclonal antibody (Sigma) was performed after stripping the nitrocellulose as suggested by the manufacturer.
Isolation and transduction of human HPCs. HPCs were harvested by leukapheresis from the peripheral blood of cancer patients treated with high-dose cyclophosphamide (7 g/m2) and hematopoietic growth factors (recombinant human GM-CSF, S pgn<yld -C rh interleukin-3, S pg/kg/d) as we have previously described." Leukapheresis aliquots were fractionated by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden), and the light-density cells were collected and exposed to filtered retroviral supernatants at a multiplicity of infection of 15: l (4 hours of incubation repeated 3 times) in the presence of protamine sulfate (5 pg/mL; Sigma). The percentage of transduced cells was assessed by PCR as described above.
For 
RESULTS
Construction of retroviral vectors expressing ALDHI.
The full-length ALDH 1 cDNA (see Materials and Methods) was subcloned into two different retroviral plasmids (Fig I) , which share the backbone of the N2 retroviral vector but differ in their 5' LTR; ie, the pLXSN vector carries the 5' LTR and part of the gag region from Moloney murine sarcoma virus,I6 whereas pE2a contains LTR sequences from the Moloney murine leukemia virus." After transfection into PA317, two clones were selected for their highest titer and used for subsequent experiments: c1.21 producing a pLXSN derivative (Aldo-X c1.21; titer, 2.5 X I O 5 pfu/mL) and cl. 26 producing a pE2a derivative (N2a-Aldo c1.26; titer, IOh plaque-forming units [pfu]/mL).
ALDHI gene transduction and expression into hematopoietic cell lines. L1210, a murine leukemia cell line, and U937, a human monoblastic leukemia cell line, were chosen as targets for ALDHI transduction because they are representative of hematopoietic precursors, show low levels of ALDH 1 RNA, and are sensitive to cyclophosphamide. These two cell lines were transduced with the supernatants of retrovirus-producing PA3 l7 clones. Northern blot analysis of ALDHI RNA expression in various clones of transduced cells (see Figs 2A and B) showed that endogenous RNA was not detectable in the N2-transduced clones, whereas a 3.4-kb (AldoX) and 5.5-kb (N2a-Aldo) RNA species corresponding in size to the viral transcripts were detectable in all the ALDH l-transduced clones.
To determine whether the ALDHI protein was expressed in transduced cells, cell extracts from different transduced clones were analyzed by immunoblotting using a rabbit polyclonal antiserum against human ALDHI (Figs 2C and D) .'" No endogenous protein was detected in N2-transduced L1210 cells, whereas a 55-kD band, corresponding to the human ALDHI protein,'y was present in all ALDHI-transduced L1 210 cells. N2a-Aldo-transduced clones consistently showed higher levels of exogenous ALDHI than AldoX-transduced clones (compare lanes 6-8 and 9-1 l in Fig  2A with lanes 4-6 and 7-9 in Fig 2C) . In U937 cells, we detected a 55-kD band corresponding to endogenously expressed ALDHI in N2-transduced U937 cells, but the same band was present at higher abundance in the N2a-Aldotransduced clones showing the expression of the transduced gene.
Assay qf ALDHl activity. A spectrophotometric assay was used to directly quantify the amount of ALDH I activity present in the soluble fraction of N2-, AldoX-, and N2a-Aldo-transduced cells'h (Fig 3) . Quantitation could be performed in L1210 cells but not in U937 cells because of their high endogenous background, which interfered with the spectrophotometric assay. As shown in Fig 3, ALDHI activity was absent or minimal in the soluble fraction of N2-transduced LI 210 cells, whereas it was increased up to threefold over basal levels on transduction with AldoX or N2a-Aldo vectors. Maphosphamide cytotoxicity assay. To determine whether increased ALDHI expression led to increased maphosphamide resistance, N2-, AldoX-, and N2a-Aldo-transduced cells were exposed to increasing doses of maphosphamide, and their ICsO was determined by the MTT or by the colony forming assay. As shown in Figs 4A and B, the ICs0 was increased in all ALDHI-transduced, but in none of the control-infected, clones. In both L1 2 IO and U937 ALDH Itransduced cells, the ICs0 was = 13 pmol/L, representing a fourfold (L1210) and a 1 S-fold (U937) increase over basal values, respectively. Dose-response curves for representative clones of L1210 and U937 cells (Figs 4C and D) indicate that ALDHI-transduced clones show some level of resistance at up to 20 pmol/ L maphosphamide. Taken together, ALDHI activity and maphosphamide toxicity results indicate that an increase in ALDHI expression is sufficient to make cells resistant to maphosphamide.
Disulfram inhibition assay. To assess the specificity of the drug resistance in transduced cells, we tested whether cyclophosphamide resistance could be reversed by pretreatment with disulfiram, a specific inhibitor of cytosolic aldehyde-dehydrogenase." Figure 5 shows that pretreatment with disulfiram caused little or no effect in control, N2-transduced, L1210 or U937 cells, whereas it completely reversed the resistance in ALDH 1 -transduced L1 2 IO and U937 cells. These results indicate that the cyclophosphamide resistance observed in ALDHI-transduced cells is specifically caused by ALDHI activity.
ALDHl gene transduction into human hematopoietic progenitor cells. We next verified whether ALDH 1 transduc- and protein (C and Dl levels in control-and ALDH1-transduced L1210 and U937 cells. For RNA analysis, 20 p g of total RNA isolated by Trizol reagent purification (see Materials and Methods) were loaded in each lane, run in a formamide gel, transferred t o a nitrocellulose filter, and hybridized t o a 32P-labeled ALDHl probe; RNA levels were normalized by hybridization with a =P-labeled GAPDH probe. For protein analysis, cell extracts from lo' L1210 cells or 2.6 x lo7 U937 cells were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis?' electrotransferred onto nitrocellulose,z8 and probed with a polyclonal antihuman ALDH rabbit antiserum" (a kind gift of Dr Yoshidal and with an anti-pactin monoclonal antibody t o control for protein amounts.
various doses of maphosphamide, and then were examined for their ability to form colonies in semisolid medium. The results obtained with HPCs from three different patients (see Figs 6A, dose-response experiment performed on HPCs in a representative patient: and B, summary of the ICso obtained with each patient) indicate that ALDHl transduction caused a significant increase in the ICso of all three patients. Similar levels of resistance (ICso, -3 to 4 pmol/L) were obtained in all three cases, including the case for which HPCs were enriched in CD34' cells before testing for maphosphamide resistance (patient no. 3; see % of CD34 cells shown in Fig  6B insert) . In one case (patient no. 2), a sufficient number of HPCs was available to test the efficiency of transduction (measured as % of cells positive for proviral DNA by PCR; see Fig 6B insert ) on cells plated in limiting dilution. Because only a fraction (62%) of the cells were positive by this assay, the levels of maphosphamide resistance must be considered as the average between those of transduced and nontransduced cells. Thus, for HPCs from patient no. 2 and most likely for the other two cases, the levels of maphosphamide resistance detected in this assay represent underestimates of the actual levels present in transduced cells. Taken together, these results indicate that ALDH 1 transduction can confer cyclophosphamide resistance to primary human hematopoietic cells in vitro.
DISCUSSION
In these experiments, we have shown that overexpression of a transduced ALDHl cDNA in human and murine hematopoietic cell lines and in human HPCs is sufficient to induce increased resistance to the cytotoxic action of maphosphamide, an active cyclophosphamide analog. These results are consistent with previous observations reporting a correlation between ALDH 1 expression and cyclophosphamide resisnomena. Thus, the ALDH 1 gene can be considered a member of the drug-resistance gene family that includes the DHFW and MDR16 genes. These findings have implications for the mechanism involved in cyclophosphamide resistance and for the use of ALDHl in gene therapy strategies in vivo. The cyclophosphamide-resistance phenotype was obtained in all ALDHl transduced clones, whereas no spontaneous resistance was detectable in controls. This, together with the specificity of the resistance phenotype shown by the enzymatic inhibition assay, formally shows the direct involvement of ALDH 1 in the cyclophosphamide-resistance phenotype. However, it can be noted (see Figs 4A and B) that the maximum levels of ICso obtained in cell lines appeared to plateau at 12 to 13 pmoVL, despite the fact that some clones had significantly higher levels of ALDH 1 RNA and protein. This observation is consistent with previous results26 showing that levels of aldehyde-dehydrogenase 1,000-fold over the basal activity did not result in a proportional induction of resistance. Thus, it is conceivable that the cyclophosphamide-resistance phenotype may be complex depending on intrinsic properties of the enzyme or its intracellular regulation and turnover and may involve the activation of multiple detoxification biochemical mechanisms. Enzymes involved in the glutathione pathway are good candidates to synergize with ALDH 1 in inducing cyclophosphamide re~istance.~*.~~ This hypothesis can be tested by constructing bicistronic retroviral vectors, expressing both the ALDHl gene and a gene implicated in glutathione metabolism.
Regardless of the possibility of further improving the phenotype, the level of resistance to maphosphamide obtained in ALDH 1 -transduced cells in vitro may already be adequate tance'o.ll and provide a causative link between the two pheto confer drug resistance in vivo. Administration of 1 @m2 cyclophosphamide, ie, a dose in the conventional range, is associated with peak serum levels of the active metabolite 4-hydroxycyclophosphamide in the 0.4-pmoVL range." Our results show that transduced cell lines and HPCs are resistant to up to 20 pmoVL and 4 pmoVL maphosphamide, respectively, suggesting that ALDH1 transduction can confer resistance to cyclophosphamide concentration well above those reached in vivo. This conclusion is also supported by the results obtained by ALDHl transduction in primary human HPCs. Using heterogeneous HPC populations from three different individuals, ALDHl transduction resulted in significant increases in maphosphamide resistance (ICso. =3 to 4 pmol/ L) up to 4-to 10-fold over control-transduced HPCs. Several observations suggest that these results underestimate the actual levels of resistance in transduced HPCs as well as the effects that these changes may have in vivo. First, in contrast to experiments performed in cell lines in which clonal populations can be examined, the levels of maphosphamide resistance in HPCs represent averages from cell populations composed of both transduced and nontransduced cells and, thus, underestimate the levels of resistance. Second, it is important to note that the endogenous ALDHl gene is expressed in early progenitor cells (HPCs), whereas it is turned off during differentiation." Thus, the colony-forming assay used in this study, in which only HPCs are exposed to the drug, fails to document the effect of ALDHl transduction and enforced expression in mature cells, where it should have the greatest effect because of their lack of endogenous ALDHl activity. Taken together, these observations suggest that, although the results obtained in HPCs provide evidence that primary hematopoiFor personal use only. on June 10, 2017. by guest www.bloodjournal.org From etic cells can be made more resistant to cyclophosphamide, only in vivo studies in experimental murine systems can provide a reliable measure of the levels and biological effects of this resistance.
The ability to render cells resistant to cyclophosphamide may be clinically useful. Cyclophosphamide, when administered in association with hematopoietic growth factors, causes a rapid decrease in peripheral blood cell counts, followed by a similarly rapid recovery to normal levels.gs This effect is derived from the ability of cyclophosphamide to kill mature HPCs (eg, CFU-GM) that lack ALDHl expression while sparing early progenitor/stem cells expressing high levels of the Based on these observations, our strategy will involve the use of autologous transplantation to reconstitute a cyclophosphamide-resistant bone marrow in which the constitutive expression of the transduced ALDHl gene should protect all mature hematopoietic cells from drug toxicity. This strategy should be useful in cancer therapy by allowing the use of protracted courses of cyclophosphamide administration. In addition, the possibility of selecting transduced hematopoietic progenitors in vivo may have more general applications by allowing the introduction of genetically engineered bone marrow cells expressing other genes of therapeutic relevance.
